Session

PP 05 IBD (Posters)

CLINICAL EFFICACY, THERAPEUTIC DRUG MONITORING AND NOCEBO EFFECT FOLLOWING NON-MEDICAL BIOSIMILAR SWITCH IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE OBSERVATIONAL STUDY
CLINICAL EFFICACY, THERAPEUTIC DRUG MONITORING AND NOCEBO EFFECT FOLLOWING NON-MEDICAL BIOSIMILAR SWITCH IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE OBSERVATIONAL STUDY

THE ROLE OF VITAMIN D STATUS ON EFFECTIVENESS OF BIOLOGIC THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
THE ROLE OF VITAMIN D STATUS ON EFFECTIVENESS OF BIOLOGIC THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY
USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY

HYPOPHOSPHATAEMIA PRIOR TO INTRAVENOUS IRON TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: IS IT MORE COMMON THAN IN THE GENERAL POPULATION?
HYPOPHOSPHATAEMIA PRIOR TO INTRAVENOUS IRON TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: IS IT MORE COMMON THAN IN THE GENERAL POPULATION?

PREDICTORS OF AN EARLY SEVERE DISEASE COURSE OF NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASES- FINDINGS FROM A DANISH POPULATION-BASED INCEPTION COHORT (IBD PROGNOSIS STUDY)
PREDICTORS OF AN EARLY SEVERE DISEASE COURSE OF NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASES- FINDINGS FROM A DANISH POPULATION-BASED INCEPTION COHORT (IBD PROGNOSIS STUDY)

CRYPT-VILLUS DYNAMICS POST-DSS EXPOSURE IN MURINE COLITIS MODEL OF INFLAMMATORY BOWEL DISEASE
CRYPT-VILLUS DYNAMICS POST-DSS EXPOSURE IN MURINE COLITIS MODEL OF INFLAMMATORY BOWEL DISEASE

LIPIDOMIC ANALYSIS OF FAECES FROM PATIENTS WITH ULCERATIVE COLITIS UNDERGOING FAECAL MICROBIOTA TRANSPLANTATION PREDICTS TREATMENT RESPONSE
LIPIDOMIC ANALYSIS OF FAECES FROM PATIENTS WITH ULCERATIVE COLITIS UNDERGOING FAECAL MICROBIOTA TRANSPLANTATION PREDICTS TREATMENT RESPONSE

STUDY OF ACTIVE SWITCHING FROM TOFACITINIB TO USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS
STUDY OF ACTIVE SWITCHING FROM TOFACITINIB TO USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS

PATIENTS WITH FIBROSTENOTIC CROHN’S DISEASE CAN TOLERATE A HIGH-FIBER, LOW-FAT DIET AND EXPERIENCE AN IMPROVEMENT IN SYMPTOMS: RESULTS OF A CATERED DIET INTERVENTION STUDY
PATIENTS WITH FIBROSTENOTIC CROHN’S DISEASE CAN TOLERATE A HIGH-FIBER, LOW-FAT DIET AND EXPERIENCE AN IMPROVEMENT IN SYMPTOMS: RESULTS OF A CATERED DIET INTERVENTION STUDY

RATIONAL SELECTION OF COMBINATION THERAPY FOR INFLAMMATORY BOWEL DISEASE TREATMENT USING AN ESTABLISHED PRECLINICAL MODEL
RATIONAL SELECTION OF COMBINATION THERAPY FOR INFLAMMATORY BOWEL DISEASE TREATMENT USING AN ESTABLISHED PRECLINICAL MODEL

EXAMINING THE ROLE OF FAECAL MICROBIOTA TRANSPLANTATION (FMT) TO INDUCE REMISSION IN RESISTANT ULCERATIVE PROCTITIS (UP)
EXAMINING THE ROLE OF FAECAL MICROBIOTA TRANSPLANTATION (FMT) TO INDUCE REMISSION IN RESISTANT ULCERATIVE PROCTITIS (UP)

ROLE OF EARLY IMMUNOMODULATOR OR BIOLOGIC THERAPY ON CLINICAL OUTCOMES IN INTESTINAL BEHÇET’S DISEASE
ROLE OF EARLY IMMUNOMODULATOR OR BIOLOGIC THERAPY ON CLINICAL OUTCOMES IN INTESTINAL BEHÇET’S DISEASE

LONG-TERM UPREGULATION OF MIR-124 IN BLOOD AND RECTAL BIOPSIES OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING OBEFAZIMOD 50 MG DAILY FOR 96-WEEKS
LONG-TERM UPREGULATION OF MIR-124 IN BLOOD AND RECTAL BIOPSIES OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING OBEFAZIMOD 50 MG DAILY FOR 96-WEEKS

IL-33/ST2 AND GUT MICROBIOTA AXIS CAN MODULATE THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS
IL-33/ST2 AND GUT MICROBIOTA AXIS CAN MODULATE THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS

HISTOLOGICAL OUTCOMES AND THE IMMUNE LANDSCAPE IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB
HISTOLOGICAL OUTCOMES AND THE IMMUNE LANDSCAPE IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB

CONTRAST-ENHANCED ULTRASOUND DISTINGUISHES INFLAMMATORY FROM NON-INFLAMMATORY STENOSIS IN CROHN’S DISEASE: FIRST RESULTS FROM THE STRICTURE STUDY
CONTRAST-ENHANCED ULTRASOUND DISTINGUISHES INFLAMMATORY FROM NON-INFLAMMATORY STENOSIS IN CROHN’S DISEASE: FIRST RESULTS FROM THE STRICTURE STUDY

MRI FACTORS ASSOCIATED WITH RELAPSE FOLLOWING DISCONTINUATION OF BIOLOGIC MEDICATION IN CROHN’S DISEASE
MRI FACTORS ASSOCIATED WITH RELAPSE FOLLOWING DISCONTINUATION OF BIOLOGIC MEDICATION IN CROHN’S DISEASE

PAEDIATRIC INFLAMMATORY BOWEL DISEASE UNCLASSIFIED IN SCOTLAND: LONG-TERM LONGITUDINAL NATURAL HISTORY DATA WITH UP TO 20 YEARS OF FOLLOW-UP
PAEDIATRIC INFLAMMATORY BOWEL DISEASE UNCLASSIFIED IN SCOTLAND: LONG-TERM LONGITUDINAL NATURAL HISTORY DATA WITH UP TO 20 YEARS OF FOLLOW-UP

PRETREATMENT SERUM MONOCYTE CHEMOATTRACTANT PROTEIN-1, BUT NOT TROUGH LEVEL, AS A PREDICTOR OF LONG-TERM OUTCOME BY USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE
PRETREATMENT SERUM MONOCYTE CHEMOATTRACTANT PROTEIN-1, BUT NOT TROUGH LEVEL, AS A PREDICTOR OF LONG-TERM OUTCOME BY USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE

MIG (CXCL9) CHEMOKINE IS A KEY BIOMARKER THAT DISCRIMINATES BETWEEN PEDIATRIC IBD PATIENTS AND NON-IBD PATIENTS IN A NOVEL BIOMARKER MODEL
MIG (CXCL9) CHEMOKINE IS A KEY BIOMARKER THAT DISCRIMINATES BETWEEN PEDIATRIC IBD PATIENTS AND NON-IBD PATIENTS IN A NOVEL BIOMARKER MODEL

Item 461 - 480 / 826
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24
25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42